RGNX
Regenxbio IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$447.49M
P/E Ratio
—
EPS
$-3.76
Beta
1.13
52W High
$16.19
52W Low
$5.15
50-Day MA
$9.17
200-Day MA
$10.49
Dividend Yield
—
Profit Margin
-113.70%
Forward P/E
—
PEG Ratio
0.26
About Regenxbio Inc
REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies intended to affect disease. The company is headquartered in Rockville, Maryland.
Fundamentals
| Revenue (TTM) | $170.44M |
| Gross Profit (TTM) | $-78.16M |
| EBITDA | $-145.58M |
| Operating Margin | -190.00% |
| Return on Equity | -107.00% |
| Return on Assets | -21.90% |
| Revenue/Share (TTM) | $3.31 |
| Book Value | $2.02 |
| Price-to-Book | 4.28 |
| Price-to-Sales (TTM) | 2.63 |
| EV/Revenue | 1.663 |
| EV/EBITDA | -3.37 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 43.00% |
| Shares Outstanding | $51.61M |
| Float | $43.00M |
| % Insiders | 8.37% |
| % Institutions | 81.15% |
Analyst Ratings
Consensus ($27.82 target)
4
Strong Buy6
Buy1
HoldData last updated: 4/9/2026